Leerink Swann Reaffirms “Outperform” Rating for Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “outperform” rating restated by stock analysts at Leerink Swann in a research report issued to clients and investors on Friday. They currently have a $18.00 price objective on the stock. Leerink Swann’s price target would indicate a potential upside of 88.28% from the company’s previous close.
KPTI has been the topic of several other reports. Jefferies Group raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating and boosted their target price for the company from $9.00 to $12.00 in a research note on Tuesday, August 30th. Robert W. Baird reissued a “positive” rating and set a $16.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, September 6th. Wedbush reissued an “outperform” rating and set a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday, August 4th. Vetr raised Karyopharm Therapeutics from a “hold” rating to a “strong-buy” rating and set a $11.00 target price on the stock in a research note on Tuesday, September 6th. Finally, Zacks Investment Research raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 21st. Two investment analysts have rated the stock with a sell rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Karyopharm Therapeutics presently has a consensus rating of “Buy” and an average target price of $16.04.
Karyopharm Therapeutics (NASDAQ:KPTI) traded down 1.54% during midday trading on Friday, hitting $9.56. The stock had a trading volume of 166,190 shares. Karyopharm Therapeutics has a 52 week low of $4.83 and a 52 week high of $19.41. The firm’s market cap is $344.05 million. The firm has a 50 day moving average of $9.04 and a 200 day moving average of $8.40.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/leerink-swann-reaffirms-outperform-rating-for-karyopharm-therapeutics-inc-kpti.html
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.08. Equities research analysts predict that Karyopharm Therapeutics will post ($3.22) EPS for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in KPTI. Schwab Charles Investment Management Inc. increased its position in Karyopharm Therapeutics by 1.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 60,498 shares of the company’s stock worth $406,000 after buying an additional 882 shares in the last quarter. Palo Alto Investors LLC increased its position in Karyopharm Therapeutics by 1.3% in the second quarter. Palo Alto Investors LLC now owns 3,139,433 shares of the company’s stock worth $21,066,000 after buying an additional 41,288 shares in the last quarter. Metropolitan Life Insurance Co. NY purchased a new position in Karyopharm Therapeutics during the second quarter worth $136,000. Highbridge Capital Management LLC purchased a new position in Karyopharm Therapeutics during the second quarter worth $200,000. Finally, New Leaf Venture Partners L.L.C. increased its position in Karyopharm Therapeutics by 1,723.5% in the second quarter. New Leaf Venture Partners L.L.C. now owns 222,947 shares of the company’s stock worth $1,496,000 after buying an additional 210,721 shares in the last quarter. 55.71% of the stock is currently owned by hedge funds and other institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.